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Introduction {#sec005}
============

The 7^th^ edition of the American Joint Committee on Cancer (AJCC) guidelines \[[@pone.0118953.ref001]--[@pone.0118953.ref002]\] for gastric cancer include many controversial changes that have been strongly debated, such as the restaging of gastric cancer and the reclassification of adenocarcinomas of the esophagogastric junction as esophageal carcinomas \[[@pone.0118953.ref003]--[@pone.0118953.ref006]\]. However, little attention has been given to the change that the station No.12a lymph nodes (lymph nodes along the proper hepatic artery) are no longer assigned to the D2 lymphadenectomy region and No.12a metastasis is reclassified accordingly as distant metastasis. Both the 6^th^ edition of AJCC guidelines \[[@pone.0118953.ref007]\] for gastric cancer and the 3^rd^ edition of Japanese treatment guidelines for gastric cancer \[[@pone.0118953.ref008]\] consider No.12a LN metastasis as regional metastasis from a primary gastric cancer that should be dissected during D2 lymphadenectomy to improve patient outcome. Moreover, most surgeons \[[@pone.0118953.ref009]--[@pone.0118953.ref010]\] agree that D2 lymphadenectomy is associated with an increased survival benefit in patients with gastric cancer. The differences between the guidelines may cause confusion among surgeons. The aim of this study was to evaluate the clinical importance and survival outcomes of patients with gastric cancer with No.12a LN metastasis and the difference in the efficacy of D2 lymphadenectomy according to the inclusion of metastatic No.12a LNs.

Methods {#sec006}
=======

The study was approved by the Institutional Review Board of the 1st Affiliated Hospital of Sun Yat-Sen University and informed consent was obtained according to institutional regulations. Written informed consent for further clinical research was given by participants for their clinical records to be used when patients were admitted to hospital.

Data obtained from patients with gastric cancer who underwent gastrectomy plus D2 or greater lymphadenectomy between January 1996 and December 2006 at the 1st affiliated hospital of Sun Yat-sen University were retrospectively analyzed. Patients who received neoadjuvant chemotherapy or chemoradiotherapy were excluded. The D2 lymphadenectomy region was determined according to the 6th edition AJCC gastric cancer guidelines and included the LNs along the left gastric artery (station No.7), the front of the common hepatic artery (station No.8a), the celiac axis (station No.9), the splenic hilum (station No.10), the splenic artery (station No.11), and the proper hepatic artery (station No.12a).

The clinicopathological features analyzed included age, sex, tumor size, histological tumor type, gross tumor type, tumor location, and cancer embryonic antigen (CEA) level. The histological type was defined as well or poorly differentiated. Poorly differentiated types included poorly differentiated adenoma, mucinous gastric cancer, signet ring cell cancer, and undifferentiated adenoma. The postoperative pathological stage was reclassified according to the 7^th^ edition of the AJCC gastric cancer guidelines.

　 Follow-up was conducted every 3--6 months for the first 3 years and once a year thereafter. Patients underwent regular blood tests including a tumor biomarker assessment, endoscopic examination, abdominal computed tomography or ultrasonography, and chest radiography or thoracic computed tomography. The last follow-up date was in December 2013. The mean follow-up time was 41.28 ± 34.84 months.

The chi-square test was used to compare differences in the categorical data. Survival was compared using the log-rank test, and survival curves were generated using the Kaplan-Meier method. The Life-table was used to calculate survival time. Univariate and multivariate analyses were conducted using the Cox proportional hazards regression model and forward logistic regression. Logistic regression analysis was used to determine factors associated with No.12a LN metastasis. A P-value \<0.05 was considered statistically significant. All data were analyzed using the Statistical Package for Social Sciences (SPSS 16.0, Chicago, IL, USA).

Results {#sec007}
=======

1. Basic information {#sec008}
--------------------

A total of 811 cases were eligible for study inclusion. Among the 247 patients with gastric cancer who underwent No.12 LN harvest, 45 (18.2%) were positive for No.12a LN metastasis. The mean number of No.12a LN metastases was 1.71 ± 1.84 (range: 1--11). To investigate the clinical significance of No.12a LN metastasis, clinicopathological characteristics were compared between cases with or without No.12a LN metastasis. Patients with No.12a LN metastasis had a large tumor size, a poor tumor histological and gross type, an abnormally high CEA level, deep tumor invasion, and extensive LN involvement ([Table 1](#pone.0118953.t001){ref-type="table"}).

10.1371/journal.pone.0118953.t001

###### Comparison of clinicopathological parameters in patients with or without No.12a station lymph nodes metastasis.

![](pone.0118953.t001){#pone.0118953.t001g}

                        No.12a(-)    No.12a(+)   *P* value
  --------------------- ------------ ----------- -----------
  Age                                            0.857
   ≤60 year             415(54.2%)   25(55.6%)   
   \>60 year            351(45.8%)   20(44.4%)   
  Gender                                         0.264
   male                 521(68.0%)   27(60.0%)   
   female               245(32.0%)   18(40.0%)   
  Tumor location                                 0.365
  Upper 1/3             230(30.0%)   12(26.7%)   
  Middle 1/3            154(20.1%)   6(13.3%)    
  lower1/3              382(49.9%)   27(60.0%)   
  Tumor diameter                                 0.003
   ≤5cm                 431(56.3%)   15(33.3%)   
   \>5cm                335(43.7%)   30(66.7%)   
  Gross type                                     0.003
   Borrmann I+II        247(32.2%)   5(11.1%)    
   Borrmann III+IV      519(67.8%)   40(88.9%)   
  Histologic grade                               0.025
   G1+G2                240(31.3%)   7(15.6%)    
   G3+G4                526(68.7%)   38(84.4%)   
  T stage(7^th^)                                 \<0.001
   T1                   110(14.4%)   0(0.0%)     
   T2                   80(10.4%)    0(0.0%)     
   T3                   131(17.1%)   1(2.2%)     
   T4                   445(58.1%)   44(97.8%)   
  N stage (7^th^)                                \<0.001
   N0                   443(57.8%)   0(0.0%)     
   N1                   92(12.0%)    3(6.7%)     
   N2                   103(13.4%)   6(13.3%)    
   N3                   128(16.7%)   36(80.0%)   
  Surgical prodecure                             0.953
   Distal gastrectomy   421(55.1%)   25(55.6%)   
   Total gastrectomy    343(44.9%)   20(44.4%)   
  CEA level                                      0.024
   ≤5mg/ml              693(90.5%)   36(80.0%)   
   \>5mg/ml             73(9.5%)     9(20.0%)    

2. Influence factors of No.12a LN metastasis {#sec009}
--------------------------------------------

Univariate logistic regression analysis revealed that tumor diameter, histological type, gross classification, T stage, N stage, and CEA level were associated with No.12a LN metastasis ([Table 2](#pone.0118953.t002){ref-type="table"}). In addition, the status of all LN stations included in the D2 dissection area, except for station No.2 LNs, influenced No.12a LN metastasis. Multivariate logistic regression analysis indicated that T stage, N stage, and No.3, 5, and 6 LN metastasis were independent predictors of No.12a LN involvement ([Table 3](#pone.0118953.t003){ref-type="table"}).

10.1371/journal.pone.0118953.t002

###### Univariate logistic regression analysis of the No.12a station lymph nodes metastasis.

![](pone.0118953.t002){#pone.0118953.t002g}

                                χ^2^ value   OR value   95% CI          *P* value
  ----------------------------- ------------ ---------- --------------- -----------
  Age                           0.033        \-         \-              0.857
  Gender                        1.246        \-         \-              0.264
  Tumor location                1.017        \-         \-              0.313
  Tumor diameter                8.483        2.573      1.362--4.861    0.004
  Gross classification          7.738        3.807      1.484--9.766    0.005
  Histological classification   4.695        2.477      1.090--5.627    0.030
  UICC T stage                  7.553        14.249     2.143--94.757   0.006
  UICC pN stage                 42.033       4.776      2.977--7.663    \<0.001
  No.1 (+)                      5.222        2.240      1.122--4.472    0.022
  No.2 (+)                      3.235        \-         \-              0.072
  No.3 (+)                      17.732       3.710      2.016--6.830    \<0.001
  No.4 (+)                      16.974       3.897      2.040--7.443    \<0.001
  No.5 (+)                      48.476       9.511      5.045--17.930   \<0.001
  No.6 (+)                      15.726       3.510      1.887--6.528    \<0.001
  No.7 (+)                      14.735       3.618      1.876--6.977    \<0.001
  No.8a (+)                     17.102       4.309      2.156--8.610    \<0.001
  No.9 (+)                      18.325       7.655      3.015--19.438   \<0.001
  No.10 (+)                     8.577        4.662      1.664--13.064   \<0.001
  No.11 (+)                     27.081       9.829      4.156--23.244   \<0.001
  CEA level                     4.850        2.373      1.100--5.122    \<0.001

10.1371/journal.pone.0118953.t003

###### Multivariate logistic regression analysis of the No.7 station lymph nodes metastasis.

![](pone.0118953.t003){#pone.0118953.t003g}

                                        X^2^ value   OR value   95% CI          P value
  ------------------------------------- ------------ ---------- --------------- ---------
  Tumor invasion depth                  4.699        8.060      1.221--53.182   0.030
  Lymph node stage                      31.495       4.210      2.549--6.956    \<0.001
  No.3 station lymph nodes metastasis   6.133        0.387      0.182--0.820    0.013
  No.5 station lymph nodes metastasis   11.542       4.569      1.902--10.976   0.001
  No.6 station lymph nodes metastasis   4.558        0.399      0.171--0.927    0.033

3. The survival significance of No.12a LN {#sec010}
-----------------------------------------

A comparison of survival between patients with or without No.12a LN metastasis revealed that those with No.12a LN metastasis had a significantly poorer survival outcome ([Table 4](#pone.0118953.t004){ref-type="table"}, [Fig. 1a](#pone.0118953.g001){ref-type="fig"}). A similar result was found between cases with or without No.12a LN metastasis in TNM I-III stages ([Table 4](#pone.0118953.t004){ref-type="table"}, [Fig. 1b](#pone.0118953.g001){ref-type="fig"}). Moreover, although No.12a LN metastasis influenced the overall survival outcome, it was not an independent predictor ([Table 5](#pone.0118953.t005){ref-type="table"}).

![1a Survival curves for patients with gastric cancer according to No. 12a lymph node status.\
Fig. 1b Survival curves for patients with TNM stage I---III according to No. 12a lymph node status. The differences in the survival curves among the subgroups were statistically significant (*p* \< 0.05).](pone.0118953.g001){#pone.0118953.g001}

10.1371/journal.pone.0118953.t004

###### The survival comparison of gastric cancer patients between No12a LN(+) and other stage.

![](pone.0118953.t004){#pone.0118953.t004g}

                                                  1ysr    3 ysr   5 ysr   *P* value   *Mst(m)*
  ----------------------------------------------- ------- ------- ------- ----------- ----------
  [Fig. 1a](#pone.0118953.g001){ref-type="fig"}                           \<0.001     
  No.12a LN(-), all stage                         78.7%   55.7%   47.4%               50.3
  No.12a LN(+), all stage                         52.8%   23.0%   15.8%               14.4
  [Fig. 1b](#pone.0118953.g001){ref-type="fig"}                           0.021       
  No.12a LN(-), TNM I-III stage                   89.6%   67.7%   58.0%               88.5
  No.12a LN(+), TNM I-III stage                   70.0%   40.0%   20.0%               32.0
  [Fig. 2a](#pone.0118953.g002){ref-type="fig"}                           0.016       
  No.12a LN(+), stage I-III                       58.9%   28.0%   19.2%               21.5
  All stage IV \[including No.12a LN(+)\]         39.9%   12.1%   7.9%                10.0
  [Fig. 2b](#pone.0118953.g002){ref-type="fig"}                           0.023       
  No.12a LN(+), stage I-III                       58.9%   28.0%   19.2%               21.5
  No.12a LN(-), stage IV                          40.7%   12.7%   8.3%                10.1
  [Fig. 2c](#pone.0118953.g002){ref-type="fig"}                           0.004       
  No.12a LN(+), stage I-III                       58.9%   28.0%   19.2%               21.5
  No.12a LN(+), stage IV                          25.0%   0.0%    0.0%                8.0
  [Fig. 2d](#pone.0118953.g002){ref-type="fig"}                           0.074       
  No.12a LN(-), stage IV                          40.7%   12.7%   8.3%                10.1
  No.12a LN(+), stage IV                          25.0%   0.0%    0.0%                8.0
  [Fig. 3a](#pone.0118953.g003){ref-type="fig"}                           \<0.001     
  N0                                              95.4%   77.6%   70.0%               136.9
  No.12a LN(-), D1 LN(+)                          91.0%   70.6%   51.9%               64.0
  No.12a LN(-), D2 LN(+)                          67.3%   28.6%   19.6%               21.5
  No.12a LN(+), stage I-III                       58.9%   28.0%   19.2%               21.5
  No.12a LN(-), stage IV                          40.7%   12.7%   8.3%                10.1
  [Fig. 3b](#pone.0118953.g003){ref-type="fig"}                           \<0.001     
  N0                                              95.4%   77.6%   70.0%               136.9
  No.12a LN(-), D1 LN(+)                          91.0%   70.6%   51.9%               64.0
  No.12a LN(-), D2 LN(+)                          67.3%   28.6%   19.6%               21.5
  No.12a LN(+), all stage                         52.8%   23.0%   15.8%               14.4
  No.12a LN(-), stage IV                          40.7%   12.7%   8.3%                10.1
  [Fig. 3c](#pone.0118953.g003){ref-type="fig"}                           0.518       
  No.12a LN(+), stage I-III                       58.9%   28.0%   19.2%               21.5
  No.12a LN(-), D2 LN(+)                          67.3%   28.6%   19.6%               21.5
  [Fig. 3d](#pone.0118953.g003){ref-type="fig"}                           0.119       
  No.12a LN(-), D2 LN(+)                          67.3%   28.6%   19.6%               21.5
  No.12a LN(+), all stage                         52.8%   23.0%   15.8%               14.4

10.1371/journal.pone.0118953.t005

###### Univariate and multivariate Cox regression survival analysis of the gastric cancer.

![](pone.0118953.t005){#pone.0118953.t005g}

                      Univariate Cox regression analysis   Multivariate Cox regression analysis                                                            
  ------------------- ------------------------------------ -------------------------------------- -------------- --------- -------- ------- -------------- ---------
  Age                 0.364                                \-                                     \-             0.547                                     
  Gender              0.201                                \-                                     \-             0.654                                     
  Tumor location      1.694                                \-                                     \-             0.193                                     
  Tumor diameter      113.577                              2.871                                  2.365--3.486   \<0.001   13.221   1.465   1.192--1.799   \<0.001
  Gross type          74.128                               2.922                                  2.289--3.730   \<0.001                                   
  Histological type   16.356                               1.559                                  1.257--1.934   \<0.001                                   
  T stage             143.363                              2.370                                  2.058--2.730   \<0.001   62.535   1.803   1.558--2.086   \<0.001
  N stage             84.221                               1.428                                  1.323--1.541   \<0.001                                   
  M stage             276.781                              5.570                                  4.550--6.820   \<0.001   18.579   1.804   1.380--2.359   \<0.001
  No.12a              30.539                               2.597                                  1.851--3.644   \<0.001                                   
  Radical surgery     318.418                              6.723                                  5.453--8.288   \<0.001   59.715   2.954   2.245--3.889   \<0.001
  CEA level           24.993                               2.007                                  1.527--2.637   \<0.001   9.828    1.556   1.180--2.051   0.002
  Chemotherapy        2.054                                \-                                     \-             0.152                                     

4. Survival comparison of No.12a LN metastasis and distant metastasis {#sec011}
---------------------------------------------------------------------

Since the 7^th^ edition of the AJCC guidelines for gastric cancer describes No.12a LN metastasis as distant metastasis, we compared the survival outcome between patients with No.12a LN metastasis and those with distant metastasis. Among the 45 patients with No.12a LN metastasis, 8 had distant metastasis. Interestingly, survival was significantly different between patients with TNM stage I--III No.12a LN metastasis and those with distant metastasis (including the 8 patients with No.12a LN metastasis). Distant metastasis was associated with a significantly worse overall survival than was No.12a LN metastasis among patients with stage I--III disease ([Fig. 2a](#pone.0118953.g002){ref-type="fig"}, [Table 4](#pone.0118953.t004){ref-type="table"}). Similar results were obtained when survival was compared between patients with No.12a LN metastasis and those with distant metastasis excluding patients with No.12a LN metastasis, among patients with stage I--III disease ([Fig. 2b](#pone.0118953.g002){ref-type="fig"}, [Table 4](#pone.0118953.t004){ref-type="table"}). In addition, the overall survival rate was significantly different between patients with TNM stage I--III No.12a LN metastasis and those with stage IV No.12a LN metastasis ([Fig. 2c](#pone.0118953.g002){ref-type="fig"}, [Table 4](#pone.0118953.t004){ref-type="table"}). Finally, the overall survival rate of patients with TNM stage IV No.12a LN metastasis was lower than that of patients with distant metastasis, although the difference was not statistically significant ([Fig. 2d](#pone.0118953.g002){ref-type="fig"}, [Table 4](#pone.0118953.t004){ref-type="table"}).

![Overall survival rates in gastric cancer patients with No.12a lymph node metastasis versus distant metastasis.\
Fig. 2a Comparison between patients with TNM stage I--III No.12a LN metastasis and those with distant metastasis (including No.12a LN metastasis). The difference in survival curves was statistically significant (*p* \< 0.05). Fig. 2b Comparison between patients with TNM stage I--III No.12a LN metastasis and those with distant metastasis (excluding No.12a LN metastasis). The difference in survival curves was statistically significant (*p* \< 0.05). Fig. 2c Comparison of patients with No.12a LN metastasis according to TNM stage I--III versus stage IV disease. The difference in survival curves was statistically significant (*p* \< 0.05). Fig. 2d Comparison of IV stage patients with No.12a LN metastasis and those with other distant metastasis. The difference in survival curves was not statistically significant (*p* \> 0.05).](pone.0118953.g002){#pone.0118953.g002}

5. Survival comparison of No.12a LN metastasis and LN involvement in other lymphadenectomy regions {#sec012}
--------------------------------------------------------------------------------------------------

Considering the significant difference in survival between patients with No.12a LN metastasis and distant metastasis, we compared survival data between patients with No.12a LN metastasis and those with metastasis in different lymphadenectomy regions to determine whether the No.12a LNs should be included in D2 lymphadenectomy. Irrespective of distant metastasis, there was a clear significant difference in overall survival among in patients with No.12a LN metastasis according to the status of different lymphadenectomy regions ([Fig. 3a--b](#pone.0118953.g003){ref-type="fig"}, [Table 4](#pone.0118953.t004){ref-type="table"}). Moreover, we found that the differences between patients with No.12a LN metastasis and LN metastasis in the D2 dissection region were similar ([Fig. 3c](#pone.0118953.g003){ref-type="fig"}, [Table 4](#pone.0118953.t004){ref-type="table"}). Similar results were obtained when comparing cases of No.12a LN metastasis excluding those of distant metastasis and cases of LN metastasis in the D2 dissection region ([Fig. 3d](#pone.0118953.g003){ref-type="fig"}, [Table 4](#pone.0118953.t004){ref-type="table"}).

![Overall survival rates for No.12a lymph node(LN) metastasis versus LN involvement in other lymphadenectomy regions.\
Fig. 3a Overall comparison between patients with No.12a LN metastasis and those with lymph node involvement in other lymphadenectomy regions. The difference in survival curves was statistically significant (*p* \< 0.05). Fig. 3b Overall comparison between patients with TNM stage I--III No.12a LN metastasis and those with lymph node involvement in other lymphadenectomy regions. The difference in survival curves was statistically significant (*p* \< 0.05). Fig. 3c Comparison between patients with No.12a LN metastasis and those with lymph node involvement in the D2 lymphadenectomy region. The difference in survival curves was not statistically significant (*p* \> 0.05). Fig. 3d Comparison between patients with TNM stage I--III No.12a LN metastasis and those with lymph node involvement in the D2 lymphadenectomy region. The difference in survival curves was not statistically significant (*p* \> 0.05).](pone.0118953.g003){#pone.0118953.g003}

Discussion {#sec013}
==========

Surgery remains the only radical treatment option for patients with gastric cancer \[[@pone.0118953.ref011]\]. After the optimistic results of a Dutch clinical trial with a 15-year follow-up \[[@pone.0118953.ref012]\], D2 lymphadenectomy was widely accepted as the standard surgical procedure for advanced gastric cancer. Currently, there are 2 main staging systems for gastric cancer: the AJCC guidelines and the Japanese treatment guidelines. The AJCC guidelines are used worldwide, but most East Asian countries use both guidelines. Regional differences in gastric cancer are existed between Asian and Western countries with respect to etiology, prevalence, clinicopathological features and treatment strategy of the disease \[[@pone.0118953.ref013]\]. Hence some guidelines of the 7th edition UICC/AJCC maybe not suitable for the Asian countries. Both guidelines extol the benefits of D2 lymphadenectomy for the treatment of gastric cancer, but recent editions propound differing opinions in this regard. For example, in the latest edition of the Japanese treatment guidelines, the range of LN dissection is no longer based on the location of gastric cancer, but is decided according to the type of gastrectomy, where both the 6^th^ and 7^th^ editions of the AJCC guidelines for gastric cancer base the extent of D2 lymphadenectomy on tumor position. Moreover, in the 7^th^ edition of the AJCC guidelines for gastric cancer, the exclusion of No.12a LN dissection from D2 lymphadenectomy, was not explained, and may result present challenges when comparing past and present data as well as data between Eastern and Western countries.

Lee et al \[[@pone.0118953.ref014]\] reported that prognosis differed between patients with hepatoduodenal (No.12) LN metastasis and those with distant metastases. Similarly, in this study, survival outcomes were similar between cases of No.12a LN metastasis and those of LN involvement in the AJCC (7^th^ edition)-defined D2 lymphadenectomy region, although survival was poorer in cases of No.12a LN metastasis than in those of distant metastasis. No.12a LN metastasis in the current study was associated with poor malignant tumor behavior and advanced tumor stage. Moreover, No.12a LN metastasis was associated with poor overall survival in patients with gastric cancer. Although the LNs along the bile duct (12b) and portal vein (12p) are excluded from the extent of regular D2 lymphadenectomy, these results support the notion that the No.12a LN metastasis should be considered as regional LN metastasis.

Limitations of the current study include its retrospective design. Therefore, this study could not address the likelihood of station No. 12a nodal metastasis in patients deemed candidates for D2 dissection. A prospective randomized controlled study is needed in the future.

In conclusion, the survival outcome of patients with No.12a LN metastasis is similar to that of patients with LN involvement in the D2 lymphadenectomy region and worse than those of patients with distant metastasis, suggesting that the No.12a LN should be included in the definition of the D2 lymphadenectomy region in the gastric cancer guidelines.
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